Search

Vered Stearns

Prospective Assessment of Patient-Reported Outcomes and Estradiol and Drug Concentrations in Patients Experiencing Toxicity from Adjuvant Aromatase Inhibitors
Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women with Early Stage Breast Cancer
[Abstract] CYP3A4*22 polymorphism is associated with increased exemestane concentrations in postmenopausal breast cancer patients
Polymorphisms in Drug-Metabolizing Enzymes and Steady-State Exemestane Concentration in Postmenopausal Patients with Breast Cancer
[Abstract] Associations between treatment-emergent symptoms and early discontinuation of aromatase inhibitor (AI) therapy

Published with Hugo Blox Builder — the free, open source website builder that empowers creators.